WuXi AppTec Co Ltd
WuXi AppTec Co Ltd is a CN-based company operating in Life Sciences Tools & Services industry. [ Read More ]
The intrinsic value of one WuXi AppTec Co Ltd stock under the Base Case scenario is 154.71 CNY. Compared to the current market price of 86.18 CNY, WuXi AppTec Co Ltd is Undervalued by 44%.
Whether you're assessing long-term stability or short-term opportunities, Historical Valuation serves as a vital tool to enhance your investment approach, enabling you to make more informed investment decisions.
Sign up to access WuXi AppTec Co Ltd's intrinsic value history.
No restrictions, no limits.
All stocks, all tools.
Look for stocks that have been historically overvalued but are now trading below their intrinsic value.
Avoid stocks that are always undervalued and never reach their intrinsic value.
Find stocks that have historically corrected quickly from being undervalued to reaching their intrinsic value.
There are two methods to calculate the Intrinsic Value of a stock: DCF Valuation and Relative Valuation. We take the average of these two methods to estimate the intrinsic value as accurately as possible. You can see the Intrinsic Value of a stock at the top of this page.
WuXi AppTec Co Ltd is a CN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Shanghai, Shanghai and currently employs 34,912 full-time employees. The company went IPO on 2018-05-08. WuXi AppTec Co., Ltd. is a China-based investment holding company principally engaged in the provision of new drug research and development (R&D), production and supporting services, as well as related technology platform services. The firm is mainly engaged in the discovery, development and production of small molecule drugs, cell therapies and gene therapies, as well as providing testing services for medical devices. The firm mainly conducts its businesses through four segments, including China-based Laboratory Services segment, Contract Manufacturing organization/contract development and manufacturing organization services (CMO/CDMO services) segment, US-based Laboratory Services segment and Clinical Research segment.